This symposium is for registrants of the ONS 38th Annual Congress.



Saturday, April 27, 2013


CE LUNCHEON SYMPOSIUM

12:30 PM to 2:00 PM


Walter E. Washington
Convention Center
Ballroom A & B
Washington, DC


PROGRAM AGENDA
12:30 PM – 12:35 PM Moderator Welcome
  Lauren Berger, MPH
The Leukemia & Lymphoma Society
   
12:35 PM – 2:00 PM Administration & Management of Current Therapies for Hematologic Malignancies
 

Kevin Brigle, PhD, ANP
Amy Goodrich, ACNP-BC
Sylvia Wood, DNP, ANP-BC

   


FACULTY

Kevin Brigle, PhD, ANP
Oncology Nurse Practitioner
Massey Cancer Center
Virginia Commonwealth University Health System
Richmond, VA

Amy Goodrich, ACNP-BC
Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, MD

Sylvia K. Wood, DNP, ANP-BC
Adult Nurse Practitioner
Associate Director, BMT Clinical Research Program
Hematologic Malignancy Stem Cell Transplant Program
Stony Brook University Medical Center
Stony Brook, NY


TARGET AUDIENCE
This activity has been designed to meet the education needs of nurses involved in the care of patients living with hematologic cancers.


PROGRAM GOAL
Oncology nursing management includes thorough knowledge of drug administration and awareness of adverse effects, including those that may cause serious and life-threatening issues. Nurses must be not only knowledgeable about administering medicines and managing possible reactions, it is also important for nurses to initiate and foster ongoing communication about side effects management and treatment adherence with both other treatment team members and with patients.

With a number of new hematologic cancer drug approvals, as well as new indications, or newly approved methods of administration for approved drugs, continuing nursing education is essential.

Through discussion of case studies, this symposium will provide the opportunity for nurses to build their knowledge about administering some of the current therapies used to treat hematologic malignancies. Monitoring and managing possible serious reactions, including infection, and communications among nurses, other treatment team members, and patients will be discussed.


EDUCATION OBJECTIVES
At the conclusion of this program, participants should be able to:

  • List three new drugs/new applications of drugs to treat patients with blood cancer
  • Explain methods of administration for two new drugs to treat patients with blood cancer
  • Describe the importance of monitoring side effects and treatment adherence
  • Identify management of two potential treatment side effects
  • Identify two communication touchpoints on side effects management and treatment adherence for nurses and patients

CONTINUING EDUCATION INFORMATION
NURSES
Approval for nurses has been obtained by the national office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

Meeting space has been assigned to provide a satellite symposium supported by The Leukemia & Lymphoma Society via an educational grant during the Oncology Nursing Society’s (ONS) 38th Annual Congress, April 25–April 28, 2013 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement nor does the Oncology Nursing Society assume any responsibility for the educational content of the symposium.


SUPPORT STATEMENT
This program is supported by grants from Millennium: The Takeda Oncology Company and Spectrum Pharmaceuticals.


AMERICANS WITH DISABILITIES ACT ADA
Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact us prior to the live event at (866) 992-9950, ext. 339.


FEE INFORMATION
There is no fee for this education activity.


This symposium is for registrants of the ONS 38th Annual Congress.

Send to a friend

For information about hematologic malignancies or LLS education programs, contact an LLS Information Specialist at (800) 955-4572 or visit www.LLS.org/professionaled.